Drug Candidates for the Treatment of Genitourinary Malignancies
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 261
Special Issue Editors
2. Postgraduate Programme in Adult Health (PPGSAD), Department of Morphology, Federal University of Maranhão (UFMA), and UFMA University Hospital (HUUFMA), 65080-805 São Luís, Brazil
Interests: cancer cachexia; animal models of cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Genitourinary malignancies include some of the most prevalent types of cancer worldwide, such as prostate, uterine, cervix and bladder cancer, as well as less prevalent lesions, including vulvar, vaginal and penile cancers. The varied etiology and the molecular heterogeneity of genitourinary cancers represent major challenges for cancer therapy. While there have been recent advances in the treatment of specific prostate and bladder cancer patient subgroups, the treatment of other less-studied diseases, such as penile cancer, remains largely unchanged. This Special Issue aims to highlight timely studies of innovative drug candidates for genitourinary cancers and their molecular targets, including pre-clinical and clinical studies, as well as review articles. Translational research studies are particularly welcome. Studies that deal with the molecular heterogeneity of genitourinary cancers and approaches to therapeutically target specific tumor subsets are also of particular interest. Finally, this Special Issue also aims to showcase studies that deal with less-studied cancers with higher incidence in developing countries, such as penile cancer.
Dr. Rui M. Gil da Costa
Dr. Haissa Oliveira Brito
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- therapeutic target
- drug discovery
- HPV
- androgen receptor
- immunotherapy
